5BT-25332-81569
4 vaccinations
2 coded responses
27 check-ins
2 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 320 / FL
- Registered
- 2020-12-23
- Relationship
- Self
- Race
- Multiracial
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-23
Registered in v-safe
-
2020-12-23
Dose 1 — Pfizer-BioNTech
- 2020-12-23
- 2020-12-27
- 2020-12-28
- 2020-12-29
- 2020-12-30
- 2021-01-06
-
2021-01-13
Dose 2 — Pfizer-BioNTech
- 2021-01-22
- 2021-01-27
- 2021-02-03
- 2021-02-10
- 2021-02-17
- 2021-02-24
- 2021-04-14
- 2021-07-14
-
2021-09-25
Dose 3 — Pfizer-BioNTech
-
2021-09-29
Survey response — days 1–6 daily, dose 3MedDRA: Lymphadenopathy — Feeling: Fair · Headache, Fatigue or tirednessFree text: Axillary lymphadenopathy on the side of the injection (left)MedDRA releases: 2024-11 · check-in free text available
- 2021-09-30
- 2021-10-01
- 2021-10-02
- 2021-10-09
- 2021-10-16
- 2021-10-23
- 2021-10-30
- 2021-11-06
- 2021-12-25
- 2022-03-26
-
2022-08-03
Dose 4 — Pfizer-BioNTech
-
2022-11-02
Survey response — 3 months, dose 4MedDRA: COVID-19, Hypertension, Office visit, Post-acute COVID-19 syndrome — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Covid infection 9/18/22, new onset uncontrolled hypertension 10/30/22 that doctors believe is due to long CovidMedDRA releases: 2024-11 · check-in free text available
-
2022-11-02
Report sent to call center — 3 months, dose 4Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
-
2022-11-03
Call successfulCompleted over the phone
- 2023-02-01
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-23 | Pfizer-BioNTech | |
| 2 | 2021-01-13 | Pfizer-BioNTech | |
| 3 | 2021-09-25 | Pfizer-BioNTech | No |
| 4 | 2022-08-03 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-11-02 | Successful 2022-11-03 |
Completed over the phone |
Free text
Release 9 — days 1–6 daily, dose 3
Systemic reaction (other): Axillary lymphadenopathy on the side of the injection (left)
Release 12 — 3 months, dose 4
Symptoms: Covid infection 9/18/22, new onset uncontrolled hypertension 10/30/22 that doctors believe is due to long Covid
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | COVID-19 | · | · | ✓ |
| SD | Hypertension | · | · | ✓ |
| SD | Office visit | · | · | ✓ |
| SD | Post-acute COVID-19 syndrome | · | · | ✓ |
| SRO | Lymphadenopathy | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release